PTPRC and neoplasm: Unlike the CT-26 model, where we saw dynamic changes in immune infiltrate throughout the course of tumor development, CD45+ cells remained relatively constant between day 3 and day 7 until shifting to roughly equal proportions of CD45- to CD45+ cells at day 10 when tumors were largest (Fig. 3c).